F
Faith L. Henderson
Researcher at Centers for Disease Control and Prevention
Publications - 7
Citations - 1943
Faith L. Henderson is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Pre-exposure prophylaxis & Emtricitabine. The author has an hindex of 7, co-authored 7 publications receiving 1755 citations.
Papers
More filters
Journal ArticleDOI
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Michael C. Thigpen,Poloko Kebaabetswe,Lynn A. Paxton,Dawn K. Smith,Charles E. Rose,Tebogo M. Segolodi,Faith L. Henderson,Sonal R Pathak,Fatma A. Soud,Kata Chillag,Rodreck Mutanhaurwa,Lovemore Ian Chirwa,Michael Kasonde,Daniel Abebe,Evans Buliva,Roman Gvetadze,Sandra H. Johnson,Thom Sukalac,Vasavi Thomas,Clyde E. Hart,Jeffrey A. Johnson,C. Kevin Malotte,Craig W. Hendrix,John T. Brooks +23 more
TL;DR: Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown.
Journal ArticleDOI
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Michael Kasonde,Richard W. Niska,Charles E. Rose,Faith L. Henderson,Tebogo M. Segolodi,Kyle Turner,Dawn K. Smith,Michael C. Thigpen,Lynn A. Paxton +8 more
TL;DR: Use of TDF-FTC was associated with a small but statistically significant decrease in BMD at the forearm, hip and lumbar spine, and a high percentage of healthy Batswana young adults had abnormal baseline BMD.
Journal ArticleDOI
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
Poloko Kebaabetswe,Michael J. Stirratt,Eleanor McLellan-Lemal,Faith L. Henderson,Simone C. Gray,Charles E. Rose,Tiffany Williams,Tiffany Williams,Lynn A. Paxton +8 more
TL;DR: Detectable drug concentrations showed modest associations with self-report and pill count adherence, and drug levels were higher among those self-reporting 100 % adherence than those reporting <100 %.
Journal ArticleDOI
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis
Lovemore Ian Chirwa,Jeffrey A. Johnson,Richard W. Niska,Tebogo M. Segolodi,Faith L. Henderson,Charles E. Rose,Jin-Fen Li,Michael C. Thigpen,Onkabetse Matlhaba,Lynn A. Paxton,John T. Brooks +10 more
TL;DR: Of the four participants who seroconverted on-study while receiving tenofovir/emtricitabine, none became infected as a result of drug-resistant HIV; moreover, no resistance mutations emerged following seroconversion.
Journal ArticleDOI
Normal Laboratory Reference Intervals among Healthy Adults Screened for a HIV Pre-Exposure Prophylaxis Clinical Trial in Botswana
Tebogo M. Segolodi,Faith L. Henderson,Charles E. Rose,Kyle T. Turner,Clement Zeh,Peter N. Fonjungo,Richard W. Niska,Clyde E. Hart,Lynn A. Paxton +8 more
TL;DR: Use of western-derived reference laboratory values to screen a group of Batswana adults resulted in many healthy people being classified as having out-of-range blood analytes.